Later Phase II investigations in melanoma proceeded fast, resulting in a landmark Phase III study that served as the foundation for the FDA’s approval of ipilimumab (Table 3), a humanized anti-CTLA-4 monoclonal antibody, for the treatment of metastatic melanoma (86–88). Here, CTLA4 is linked to melanoma.